Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults
Abstract Background We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in mi...
Saved in:
Published in | The Journal of infectious diseases Vol. 227; no. 1; pp. 103 - 112 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
28.12.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-1899 1537-6613 1537-6613 |
DOI | 10.1093/infdis/jiac433 |
Cover
Abstract | Abstract
Background
We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection.
Methods
Serosusceptible subjects aged 18–49 years were randomized to receive 2 doses (108–109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines.
Results
The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%–56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%–92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%–85.8%) of recipients. Mucosal and cellular immune responses were also induced.
Conclusions
These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza.
Clinical Trials Registration
NCT03999554.
High dose of intranasal single replication M2SR influenza vaccine enhances mucosal and serum antibodies against drifted H3N2 influenza viruses. Serum microneutralization titer was shown to be a marker of protection against highly drifted H3N2 influenza in a previous challenge study.
Lay Summary
In recent years, influenza A H3N2 viruses have evolved into multiple cocirculating clades, resulting in low vaccine efficacy and highlighting the need for more effective influenza vaccines. In a previous challenge study, a single intranasal dose of the investigational vaccine M2SR demonstrated protection against a highly drifted H3N2 influenza challenge virus in a subset of vaccine recipients with a signature immune response.
Increasing the dose of the M2SR vaccine in this phase1b study demonstrated a statistically significant increase in the proportion of subjects with the signature immune responses seen previously. The vaccine-induced antibodies were cross-reactive with a panel of drifted H3N2 viruses from 2007 to 2019.
Additionally, M2SR generated a rise in serum hemagglutination inhibition antibody titer in 71% of subjects. In contrast, the H3N2 seroresponse rate for the licensed intranasal vaccine FluMist is 10% in seronegative adults. Moreover, M2SR elicited mucosal and cell-mediated immune responses.
This study demonstrates that the intranasal M2SR generates a multifaceted immune response and has the potential to provide better efficacy against vaccine-matched strains and influenza drift variants reducing the need to update the vaccine on an annual basis. This is a noteworthy step in the development of a broadly protective influenza vaccine. |
---|---|
AbstractList | Background We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection. Methods Serosusceptible subjects aged 18–49 years were randomized to receive 2 doses (108–109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines. Results The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%–56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%–92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%–85.8%) of recipients. Mucosal and cellular immune responses were also induced. Conclusions These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza. Clinical Trials Registration NCT03999554. We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection. Serosusceptible subjects aged 18-49 years were randomized to receive 2 doses (108-109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines. The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%-56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%-92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%-85.8%) of recipients. Mucosal and cellular immune responses were also induced. These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza. NCT03999554. Abstract Background We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection. Methods Serosusceptible subjects aged 18–49 years were randomized to receive 2 doses (108–109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines. Results The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%–56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%–92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%–85.8%) of recipients. Mucosal and cellular immune responses were also induced. Conclusions These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza. Clinical Trials Registration NCT03999554. High dose of intranasal single replication M2SR influenza vaccine enhances mucosal and serum antibodies against drifted H3N2 influenza viruses. Serum microneutralization titer was shown to be a marker of protection against highly drifted H3N2 influenza in a previous challenge study. Lay Summary In recent years, influenza A H3N2 viruses have evolved into multiple cocirculating clades, resulting in low vaccine efficacy and highlighting the need for more effective influenza vaccines. In a previous challenge study, a single intranasal dose of the investigational vaccine M2SR demonstrated protection against a highly drifted H3N2 influenza challenge virus in a subset of vaccine recipients with a signature immune response. Increasing the dose of the M2SR vaccine in this phase1b study demonstrated a statistically significant increase in the proportion of subjects with the signature immune responses seen previously. The vaccine-induced antibodies were cross-reactive with a panel of drifted H3N2 viruses from 2007 to 2019. Additionally, M2SR generated a rise in serum hemagglutination inhibition antibody titer in 71% of subjects. In contrast, the H3N2 seroresponse rate for the licensed intranasal vaccine FluMist is 10% in seronegative adults. Moreover, M2SR elicited mucosal and cell-mediated immune responses. This study demonstrates that the intranasal M2SR generates a multifaceted immune response and has the potential to provide better efficacy against vaccine-matched strains and influenza drift variants reducing the need to update the vaccine on an annual basis. This is a noteworthy step in the development of a broadly protective influenza vaccine. We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection.BACKGROUNDWe previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine protected against highly drifted H3N2 influenza challenge in a subset of subjects who demonstrated ≥2-fold increase in microneutralization (MN) antibodies to Belgium2015 (the challenge strain) after vaccination. Here, we describe a phase 1b, observer-blinded, dose-escalation study demonstrating an increased proportion of responders with this signal of immune protection.Serosusceptible subjects aged 18-49 years were randomized to receive 2 doses (108-109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines.METHODSSerosusceptible subjects aged 18-49 years were randomized to receive 2 doses (108-109 TCID50) of M2SR or placebo administered 28 days apart. Clinical specimens were collected before and after each dose. The primary objective was to demonstrate safety of M2SR vaccines.The vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%-56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%-92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%-85.8%) of recipients. Mucosal and cellular immune responses were also induced.RESULTSThe vaccine was well tolerated at all dose levels. Against Belgium2015, ≥ 2-fold increases in MN antibodies were noted among 40% (95% confidence interval [CI], 24.9%-56.7%) of subjects following a single 108 TCID50 M2SR dose and among 80.6% (95% CI, 61.4%-92.3%) after 109 dose (P < .001). A single 109 TCID50 dose of M2SR generated ≥4-fold hemagglutination inhibition antibody seroconversion against the vaccine strain in 71% (95% CI, 52.0%-85.8%) of recipients. Mucosal and cellular immune responses were also induced.These results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza.CONCLUSIONSThese results indicate that M2SR may provide substantial protection against infection with highly drifted strains of H3N2 influenza.NCT03999554.CLINICAL TRIALS REGISTRATIONNCT03999554. |
Author | Coelingh, Kathleen Herber, Renee Greenberg, Harry Belshe, Robert Hatta, Yasuko Fierro, Carlos Marshall, David Aitchison, Roger Schwartz, Howard Kawaoka, Yoshihiro Eiden, Joseph Neumann, Gabriele Bilsel, Pamuk Moser, Michael J Ellis, Kimberly J Adams, Mark |
Author_xml | – sequence: 1 givenname: Joseph surname: Eiden fullname: Eiden, Joseph – sequence: 2 givenname: Carlos surname: Fierro fullname: Fierro, Carlos – sequence: 3 givenname: Howard surname: Schwartz fullname: Schwartz, Howard – sequence: 4 givenname: Mark surname: Adams fullname: Adams, Mark – sequence: 5 givenname: Kimberly J surname: Ellis fullname: Ellis, Kimberly J – sequence: 6 givenname: Roger surname: Aitchison fullname: Aitchison, Roger – sequence: 7 givenname: Renee surname: Herber fullname: Herber, Renee – sequence: 8 givenname: Yasuko surname: Hatta fullname: Hatta, Yasuko – sequence: 9 givenname: David surname: Marshall fullname: Marshall, David – sequence: 10 givenname: Michael J surname: Moser fullname: Moser, Michael J – sequence: 11 givenname: Robert surname: Belshe fullname: Belshe, Robert – sequence: 12 givenname: Harry surname: Greenberg fullname: Greenberg, Harry – sequence: 13 givenname: Kathleen surname: Coelingh fullname: Coelingh, Kathleen – sequence: 14 givenname: Yoshihiro surname: Kawaoka fullname: Kawaoka, Yoshihiro – sequence: 15 givenname: Gabriele surname: Neumann fullname: Neumann, Gabriele – sequence: 16 givenname: Pamuk surname: Bilsel fullname: Bilsel, Pamuk email: PBilsel@flugen.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36350017$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkctv1DAQhy1U1G4fV47IEpf2kK4dOw8fV6W0K3Wh6gLXyHEm4JV3nMYxqL3xn5OShUMl1NNcvt88vjkke-gRCHnD2TlnSswtto0N843VRgrxisx4Jookz7nYIzPG0jThpVIH5DCEDWNMirzYJwciFxljvJiRX0sceo06aEdX6fqOnq7S5D201ljAga4tfnNA76Bz1ujBejyj1-JjSpfYugj4qOlXbYxFoLe9_2EbCPQSv2s00NBVNP6pr8aGrqGPW7rAwda-sSNlkS6a6IZwTF632gU42dUj8uXD5eeL6-Tm09XyYnGTGKGKISnaWmUiM8CgrSWXWVO2JS-ZMiWHXEoGtWEl45nMpGKCp7nMlcxTpU1Zg1LiiMynvhE7_fBTO1d1vd3q_qHirHqSWU0yq53MMXE6Jbre30cIQ7W1wYBzGsHHUKWFkKPoskhH9N0zdONjj-M9leB5UYx7smyk3u6oWG-h-Tf_7ztGQE6A6X0IPbSVscMf7eOTrPv_oufPYi9edjYFfOxeYn8DrEG9yw |
CitedBy_id | crossref_primary_10_1080_21505594_2024_2316459 crossref_primary_10_3390_vaccines11061063 crossref_primary_10_1016_S1473_3099_24_00351_7 crossref_primary_10_1038_s41392_024_02043_4 crossref_primary_10_3390_vaccines12111228 crossref_primary_10_1016_j_vaccine_2024_126408 crossref_primary_10_1093_infdis_jiae361 crossref_primary_10_1080_14760584_2024_2326094 crossref_primary_10_1080_22221751_2023_2281355 crossref_primary_10_3390_vaccines10122131 crossref_primary_10_3390_vaccines11040798 crossref_primary_10_1016_j_vaccine_2024_03_040 |
Cites_doi | 10.1016/j.trivac.2014.08.001 10.1093/cid/ciz411 10.1016/j.vaccine.2016.08.061 10.1016/j.vaccine.2018.06.053 10.1016/j.vaccine.2009.05.099 10.1111/j.1750-2659.2010.00183.x 10.1016/S0264-410X(99)00334-5 10.1111/irv.12664 10.1080/21645515.2017.1377376 10.1128/AAC.00517-07 10.1016/S1473-3099(11)70295-X 10.1093/infdis/jiab374 10.1038/nm.2612 10.1371/journal.pone.0002574 10.1086/315323 10.1016/j.vaccine.2017.06.039 10.1128/jcm.24.1.157-160.1986 10.3390/vaccines9121388 10.1089/08828240260066242 |
ContentType | Journal Article |
Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
DBID | TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 ADTOC UNPAY |
DOI | 10.1093/infdis/jiac433 |
DatabaseName | Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 112 |
ExternalDocumentID | 10.1093/infdis/jiac433 36350017 10_1093_infdis_jiac433 |
Genre | Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S Journal Article |
GroupedDBID | --- -DZ -~X ..I .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 123 1KJ 1TH 29K 2AX 2WC 36B 3O- 4.4 41~ 48X 53G 5GY 5RE 5VS 5WD 6.Y 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYOK ABBHK ABDFA ABDPE ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPTD ABQLI ABQNK ABSAR ABSMQ ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACGOD ACHIC ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFQV AFFZL AFHKK AFIYH AFOFC AFQQW AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BTRTY BVRKM BZKNY C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DOOOF DU5 D~K EBS ECGQY EE~ EIHJH EJD EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HQ3 HTVGU HW0 HZ~ IH2 IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JSODD JST KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 M49 MBLQV MHKGH MJL ML0 MVM N4W N9A NEJ NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P0- P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TOX TR2 VH1 VXZ W2D W8F WH7 X7H X7M Y6R YAYTL YIF YKOAZ YXANX ZE2 ZGI ZKG ZXP ~91 AAYXX ABPQP ADNBA AEMQT AHGBF AJBYB AJNCP ALXQX CITATION JXSIZ CGR CUY CVF ECM EIF NPM AGORE K9. NAPCQ 7X8 AAFWJ ACVCV ADMTO ADQXQ ADTOC AJDVS AVNTJ OBFPC UNPAY |
ID | FETCH-LOGICAL-c397t-7fb9535ce0efb4145d8f81809c81e6440ebc080154549031264694629ac8be993 |
IEDL.DBID | UNPAY |
ISSN | 0022-1899 1537-6613 |
IngestDate | Wed Oct 01 15:14:41 EDT 2025 Sat Sep 27 22:50:53 EDT 2025 Mon Jun 30 10:38:24 EDT 2025 Wed Feb 19 02:26:08 EST 2025 Wed Oct 01 02:15:57 EDT 2025 Thu Apr 24 23:03:38 EDT 2025 Tue Feb 18 07:36:34 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | influenza vaccine intranasal H3N2 live drift mucosal |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc-nd/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. cc-by-nc-nd |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c397t-7fb9535ce0efb4145d8f81809c81e6440ebc080154549031264694629ac8be993 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://academic.oup.com/jid/article-pdf/227/1/103/48438821/jiac433.pdf |
PMID | 36350017 |
PQID | 3167780905 |
PQPubID | 41591 |
PageCount | 10 |
ParticipantIDs | unpaywall_primary_10_1093_infdis_jiac433 proquest_miscellaneous_2734613872 proquest_journals_3167780905 pubmed_primary_36350017 crossref_citationtrail_10_1093_infdis_jiac433 crossref_primary_10_1093_infdis_jiac433 oup_primary_10_1093_infdis_jiac433 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-12-28 |
PublicationDateYYYYMMDD | 2022-12-28 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-28 day: 28 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAlternate | J Infect Dis |
PublicationYear | 2022 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Hatta (2022122814513864500_jiac433-B14) 2017; 35 Murphy (2022122814513864500_jiac433-B22) 2002; 15 Eiden (2022122814513864500_jiac433-B17) 2022; 226 Coelingh (2022122814513864500_jiac433-B20) 2014; 3 Belongia (2022122814513864500_jiac433-B1) 2019; 69 Wilkinson (2022122814513864500_jiac433-B4) 2012; 18 Mohn (2022122814513864500_jiac433-B12) 2018; 14 Clements (2022122814513864500_jiac433-B5) 1986; 24 He (2022122814513864500_jiac433-B10) 2008; 3 Osterholm (2022122814513864500_jiac433-B8) 2012; 12 Eiden (2022122814513864500_jiac433-B13) 2021; 9 Belshe (2022122814513864500_jiac433-B7) 2000; 181 Gianchecchi (2022122814513864500_jiac433-B18) 2019; 13 Hatta (2022122814513864500_jiac433-B16) 2018; 36 Ambrose (2022122814513864500_jiac433-B21) 2011; 5 Treanor (2022122814513864500_jiac433-B6) 1999; 18 Sarawar (2022122814513864500_jiac433-B15) 2016; 34 Centers for Disease Control and Prevention (2022122814513864500_jiac433-B3) 2022 Hobson (2022122814513864500_jiac433-B19) 1972; 70 Block (2022122814513864500_jiac433-B11) 2007; 51 Karron (2022122814513864500_jiac433-B9) 2009; 27 World Health Organization (2022122814513864500_jiac433-B2) 2021 |
References_xml | – volume: 3 start-page: 150 year: 2014 ident: 2022122814513864500_jiac433-B20 article-title: An integrated multi-study analysis of serum HAI antibody responses to Ann Arbor strain live attenuated influenza vaccine in children and adults publication-title: Trials Vaccinol doi: 10.1016/j.trivac.2014.08.001 – volume: 69 start-page: 1817 year: 2019 ident: 2022122814513864500_jiac433-B1 article-title: Influenza vaccine effectiveness: defining the H3N2 problem publication-title: Clin Infect Dis doi: 10.1093/cid/ciz411 – year: 2021 ident: 2022122814513864500_jiac433-B2 – volume: 34 start-page: 5090 year: 2016 ident: 2022122814513864500_jiac433-B15 article-title: M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice publication-title: Vaccine doi: 10.1016/j.vaccine.2016.08.061 – volume: 36 start-page: 5097 year: 2018 ident: 2022122814513864500_jiac433-B16 article-title: Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity publication-title: Vaccine doi: 10.1016/j.vaccine.2018.06.053 – volume: 27 start-page: 4953 year: 2009 ident: 2022122814513864500_jiac433-B9 article-title: Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults publication-title: Vaccine doi: 10.1016/j.vaccine.2009.05.099 – volume: 5 start-page: 67 year: 2011 ident: 2022122814513864500_jiac433-B21 article-title: The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults publication-title: Influenza Other Respir Viruses doi: 10.1111/j.1750-2659.2010.00183.x – volume: 18 start-page: 899 year: 1999 ident: 2022122814513864500_jiac433-B6 article-title: Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses publication-title: Vaccine doi: 10.1016/S0264-410X(99)00334-5 – volume: 13 start-page: 429 year: 2019 ident: 2022122814513864500_jiac433-B18 article-title: How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12664 – volume: 14 start-page: 571 year: 2018 ident: 2022122814513864500_jiac433-B12 article-title: Immune responses after live attenuated influenza vaccination publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2017.1377376 – volume: 51 start-page: 4001 year: 2007 ident: 2022122814513864500_jiac433-B11 article-title: Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00517-07 – volume: 12 start-page: 36 year: 2012 ident: 2022122814513864500_jiac433-B8 article-title: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(11)70295-X – volume: 226 start-page: 83 year: 2022 ident: 2022122814513864500_jiac433-B17 article-title: M2-deficient single-replication influenza vaccine-induced immune responses associated with protection against human challenge with highly drifted H3N2 influenza strain publication-title: J Infect Dis doi: 10.1093/infdis/jiab374 – volume: 18 start-page: 274 year: 2012 ident: 2022122814513864500_jiac433-B4 article-title: Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans publication-title: Nat Med doi: 10.1038/nm.2612 – volume: 3 start-page: e2574 year: 2008 ident: 2022122814513864500_jiac433-B10 article-title: Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines publication-title: PLoS One doi: 10.1371/journal.pone.0002574 – volume: 181 start-page: 1133 year: 2000 ident: 2022122814513864500_jiac433-B7 article-title: Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine publication-title: J Infect Dis doi: 10.1086/315323 – volume: 35 start-page: 4177 year: 2017 ident: 2022122814513864500_jiac433-B14 article-title: M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza publication-title: Vaccine doi: 10.1016/j.vaccine.2017.06.039 – year: 2022 ident: 2022122814513864500_jiac433-B3 – volume: 24 start-page: 157 year: 1986 ident: 2022122814513864500_jiac433-B5 article-title: Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus publication-title: J Clin Microbiol doi: 10.1128/jcm.24.1.157-160.1986 – volume: 9 start-page: 1388 year: 2021 ident: 2022122814513864500_jiac433-B13 article-title: Safety and immunogenicity of M2-deficient, single replication, live influenza vaccine (M2SR) in adults publication-title: Vaccines (Basel) doi: 10.3390/vaccines9121388 – volume: 15 start-page: 295 year: 2002 ident: 2022122814513864500_jiac433-B22 article-title: Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines publication-title: Viral Immunol doi: 10.1089/08828240260066242 – volume: 70 start-page: 767 year: 1972 ident: 2022122814513864500_jiac433-B19 article-title: The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses publication-title: J Hyg (Lond) |
SSID | ssj0004367 |
Score | 2.486187 |
Snippet | Abstract
Background
We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication... We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR) influenza vaccine... Background We previously demonstrated that an intranasal dose of 108 50% tissue culture infectious dose (TCID50) M2-deficient single replication (M2SR)... |
SourceID | unpaywall proquest pubmed crossref oup |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 103 |
SubjectTerms | Adult Antibodies Antibodies, Viral Cell culture Clinical trials Hemagglutination inhibition Hemagglutination Inhibition Tests Humans Immune response Immune response (cell-mediated) Influenza Influenza A Virus, H3N2 Subtype Influenza Vaccines Influenza, Human Mucosal immunity Replication Seroconversion Tissue culture Vaccination Vaccines |
Title | Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36350017 https://www.proquest.com/docview/3167780905 https://www.proquest.com/docview/2734613872 https://academic.oup.com/jid/article-pdf/227/1/103/48438821/jiac433.pdf |
UnpaywallVersion | publishedVersion |
Volume | 227 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: KQ8 dateStart: 19970401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 20241002 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: DIK dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1537-6613 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004367 issn: 1537-6613 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED9tnfh64GN8BcZkEBLjwW1jJ6nzWMG2DqllYisqT5HtOFqhuBVJhLY3_nPOzYc2JDQeeMlLLk4c3_l-tu9-B_BaiSjESU5Qzn1JA55KKlJtKE8Z0ybqc65dvvN4Eo2mwYdZONuAwyYXRtZR4d0mpeErjkn9E-kqzXoM1-o-2jrvBSLgiA99FJE64LgmTLNN2IrcSVMHtqaT4-GXhivcF-tKkmjeA4oeibf0jbyHA5nO86aRK-7pSsrbJeR5B26VdiXPf8rF4pI3OrgHZ00_qiCUb92yUF198QfF43_o6H24WyNWMqweegAbxm7DjaqG5fk23BzXp_MP4deR2ym2MkfxMTv5RPbGjL43jqMCXRs5QS-5MAQhf7NR-JaM-ISRo6pQyoUkn6V2TZHjKj8wJ_v2bB2iQMYush7blTYlOL-V38nQFnO1dEGQZG7J0PGI5I9gerB_-m5E6xIPVCMQKuggU3HIQ236JlOBH4SpyFz2eayFbxCq9Y1yVOgO5wUxzj8I36I4iFgstVAGsdVj6NilNU-BRFwabUKu4lQEQoa4EkRtk6hyvlRMKA9oM7KJrvnPXRmORVKdw_Ok0oSk_ssevGnlVxXzx18lX-EgXiu00-hRUk8TeeJoCAbY237owcv2Nhq4O7WR1izLPHH8Q6ixYsA8eFLpX_sqjnDR4QwP9lqFvOY7nv276HO4zdbG4xL4d6BT_CjNC4RghdqFzcOZj9fTj7Pd2tR-A_qLL6o |
linkProvider | Unpaywall |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-NTnw98DEYBAYyCInx4LaJndR5rGCjQ0o1MYq2p8h2HK2juBVJhLY3_nPOzYc2JDQeeM7Fie0738_23e8A3igRhbjICcqYLylnmaQi04ayLAi0iYaMaZfvnEyjyYx_Og6PN-Bjmwsjm6jwfpvScIZz0gwiXWX5IMC9uo-2zgZccIb40EcRqTnDPWGW34DNyN009WBzNj0cn7Rc4b5YV5JE8x5R9Eiso29kA5zIbF60jVxxT1dS3i4hz7twu7Iref5TLhaXvNH-fTht-1EHoXzrV6Xq64s_KB7_Q0cfwL0GsZJx_dJD2DB2C27WNSzPt-BW0tzOP4JfB-6k2MoCxZPg6DPZTQL6wTiOCnRt5Ai95MIQhPztQeE7MmHTgBzUhVIuJPkqtWuKHNb5gQXZs6frEAWSuMh6bFfajOD6Vn0nY1vO1dIFQZK5JWPHI1I8htn-3pf3E9qUeKAagVBJR7mKQxZqMzS54j4PM5G77PNYC98gVBsa5ajQHc7jMa4_CN-imEdBLLVQBrHVNvTs0pqnQCImjTYhU3EmuJAh7gRR2ySqnC9VIJQHtJ3ZVDf8564MxyKt7-FZWmtC2oyyB287-VXN_PFXydc4idcK7bR6lDbLRJE6GoIR9nYYevCqe4wG7m5tpDXLqkgd_xBqrBgFHjyp9a_7FEO46HCGB7udQl7zH8_-XfQ53AnWxuMS-HegV_6ozAuEYKV62ZjXb9AbLZ0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intranasal+M2SR+%28M2-Deficient+Single+Replication%29+H3N2+Influenza+Vaccine+Provides+Enhanced+Mucosal+and+Serum+Antibodies+in+Adults&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Eiden%2C+Joseph&rft.au=Fierro%2C+Carlos&rft.au=Schwartz%2C+Howard&rft.au=Adams%2C+Mark&rft.date=2022-12-28&rft.eissn=1537-6613&rft.volume=227&rft.issue=1&rft.spage=103&rft_id=info:doi/10.1093%2Finfdis%2Fjiac433&rft_id=info%3Apmid%2F36350017&rft.externalDocID=36350017 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |